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4. General Introduction 
 
Pancreatic islet transplantation can provide glycemic control and insulin independence for 
patients with type 1 diabetes. Pancreatic islets are highly vulnerable during the immediate post-
transplantation period. Long-term monitoring of transplanted islets with a reliable and 
noninvasive imaging technology is an unmet clinical need. The main goal of the present studies 
was to develop a technique for in vivo visualization of human pancreatic islets transplanted in 
mouse and baboon models of Type 1 diabetes mellitus using a high-resolution magnetic 
resonance imaging (MRI). 
 
4.1 Type 1 Diabetes Mellitus 
 
Type 1 diabetes mellitus (T1DM) is one of the most common endocrine problems in childhood 
and adolescence, and remains a serious chronic disorder with increased morbidity and mortality 
and reduced quality of life [1]. According to the American Centers for Disease Control about 1.3 
million people in the United States have T1DM. More than 13,000 young people are diagnosed 
with T1DM each year [2]. In Europe, the incidence of T1DM in children younger than 15 years 
increases by 3.9% annually. If a present trend continues, doubling of new cases of T1DM in 
European children younger than 5 years is predicted by 2020, and prevalent cases younger than 
15 years will rise by 70% [3]. Medical management of patients with T1DM is associated with a 
six- to sevenfold higher direct costs than medical management of the age-matched non-diabetics 
[4]. 
Type 1 diabetes mellitus is chronic autoimmune disease in genetically predisposed individuals 
clinically characterized by hyperglycemia [5]. Regulation of blood glucose concentrations 
requires an adequate number of functioning pancreatic beta-cells able to respond to fluctuating 
glucose levels by secreting insulin. Pancreatic islets or the islets of Langerhans are vascularized 
clusters of cells within the pancreas that contain the insulin-producing beta-cells. They were 
named after Paul Langerhans who provided the first comprehensive description of their histology 
in his dissertation in 1869 [6]. There are five types of cells within an islet: α, β, δ, pp, and ε cells 
that secrete glucagon, insulin, somatostatin, pancreatic polypeptide, and ghrelin, respectively. In 
islets, there are 36.4-72.4% of insulin-positive cells, 12.4-48.2 % of glucagon-positive cells, 2.9-
29.5% of somatostatin-positive cells, 0.5-4.2% of pancreatic polypeptide-positive cells [7]. In 
diabetic patients, a targeted inflammatory reaction against insulin secreting beta-cells in the islets 
of Langerhans results in a gradual loss of beta-cells [8, 9]. In order to maintain physiological 
levels of blood glucose, patients require lifelong insulin replacement therapy combined with 
tailored diet and physical exercise [10]. 
 
4.2 Current Management of Type 1 Diabetes 
Insulin replacement therapy is based on multiple insulin injections and frequent assessment of 
glycemic control. Diabetic patients with poor glycemic control experience numerous life 
threatening, disease-associated microvascular (retinopathy, neuropathy, and nephropathy) and 
macrovascular (coronary and peripheral vessel disease) complications [10]. The goal of the 
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intensive insulin therapy is to keep the blood glucose level within the normal range. Long-term 
maintenance of euglycemia significantly delays the progression of chronic diabetic 
complications [11‐13]. Nevertheless, intensive insulin therapy is associated with a high rate of 
severe hypoglycemia in most people with T1DM. The average patient has numerable numbers of 
episodes of asymptomatic hypoglycemia and suffers two episodes of symptomatic hypoglycemia 
per week (with thousands of such episodes over a lifetime of diabetes). Diabetic patients suffer 
from one or more episodes of severe, temporarily disabling hypoglycemia, often accompanied 
with seizure or coma, per year [14]. Hypoglycemia remains a significant barrier to achieving 
lower levels of glycated hemoglobin (HbA1c). Less than 57% of individuals with T1DM are 
achieving target HbA1c levels [15‐18]. Even with the currently available sophisticated insulin 
pumps and continuous glucose monitoring devices, the majority of patients with diabetes 
struggle to achieve optimal glycemic control. The most advanced recent technology (an artificial 
pancreas or a closed-loop insulin delivery system) is still under development and faces various 
physiological challenges and technical issues, including variability in insulin requirement, delay 
in insulin action and alterable accuracy of glucose sensors [19].  
These observations encourage researchers to explore alternative methods of restoring 
physiological blood glucose regulation. Beta-cell replacement is the only treatment that 
reestablishes and maintains long-term glucose homeostasis with near-perfect feedback controls 
[20]. Whole pancreas transplantation and pancreatic islets transplantation are effective beta-cell 
replacement therapies for diabetic patients with negative stimulated C-peptide (≤0.3 ng/ml) [21]. 
Islet transplantation has recently emerged as a minimally invasive alternative to restore 
normoglycemia in diabetic patients. Islet transplantation is preformed by an infusion of islets via 
microembolization into the hepatic portal venous system. The islets entrapping occurs in its 
peripheral branches, at presinusoid level because of the size restriction followed by their 
engraftment and neovascularization from the hepatic vasculature. Once lodged in the vessels 
branching from the portal vein, the islets have direct contact with blood, which enables them to 
continuously detect blood sugar levels and, at the same time, to receive continuous nourishment 
[22‐26]. 
The first successful islet transplantation was performed in 1972 when the Lacy’s research 
group demonstrated that intraperitoneal transplantation of pancreatic islets ameliorates the effect 
of chemically-induced diabetes in rats [27]. Kemp demonstrated that the liver was the most 
physiological environment for islet implantation in rodents, because normally insulin from the 
pancreatic beta-cells is secreted directly into the portal venous system [28]. Najarian performed 
the first successful clinical islet allotransplant in 1977 [29]. In 1979, Largiader reported the first 
C-peptide-negative diabetic patient to achieve insulin independence at one year after a 
simultaneous kidney and islet transplantation [30]. 
However, of the 237 well-documented allotransplants in T1DM patients recorded in the Islet 
Transplant Registry (ITR) database in Giessen, Germany between 1990 and 1999, less than 12% 
of recipients were insulin-free at 1 yr posttransplant. Graft survival, defined as basal C-peptide 
higher than 0.5 ng/mL, was 41% [31]. The limited success of early clinical islet transplants 
revealed that conventional immunosuppressants were relatively ineffective in preventing 
allograft rejection. Most, if not, all the immunosuppressive agents were associated with impaired 
beta-cell function, reduced graft revascularization, or serious long-term side effects such as 
nephrotoxicity and malignancy [32, 33]. 
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In 2000, Shapiro’s group introduced the “Edmonton protocol”, a new glucocorticoid-free 
immunosuppressive regimen comprised of daclizumab, sirolimus, and tacrolimus [24]. In their 
study, all seven patients became independent from exogenous insulin therapy once sufficient 
numbers of islets were transplanted. Patients required up to 3 subsequent islet transplantations 
from multiple donors in order to obtain a sufficient quantity of beta-cells, as certain amount of 
islets was lost during the early posttransplant period. The remaining islets were well protected by 
the new immunosuppressive therapy and allowed 100% insulin independence at 1 year 
posttransplant [24]. Subsequent studies confirmed that long-term insulin independence was 
possible and that this therapy was safe and well tolerated [34-37]. 
During the last decade, the immunosuppressive protocol and islets isolation technique were 
further improved, so the recipients who received islet grafts after 2005 retained insulin 
independence significantly longer than those transplanted between 1999 and 2004 [38, 39]. The 
Collaborative Islet Transplant Registry (CITR) included data on 571 allogeneic islet 
transplantation recipients (481 islet transplantations alone and 90 islet transplantations after or 
simultaneously with kidney transplantations), who received 1,072 infusions from 1,187 donors 
during 1999-2009 [39]. Overall, non-stratified achievement of insulin independence was 65% in 
the first year post the first infusion (with or without reinfusion). Nevertheless, the proportion of 
patients that was insulin independent without reinfusion (utilizing islets from a single donor) 
remained low, at 30% throughout the first year and 18% at 5 years post-transplantation, 
respectively [39]. For islet transplantations to become a widespread clinical reality, diabetes 
reversal should be achieved with a single donor to reduce risks and costs and increase the overall 
availability [38, 40]. 
 
4.3 Barriers to Successful Clinical Islet Transplantation 
Long-term insulin independence after a single-donor islets infusion is the ultimate goal of 
transplantation studies [38, 40, 41]; however, a sufficient number of islets derived from two or 
more donor pancreas are usually required to achieve insulin independence. The need for multiple 
donors is a serious drawback given the prevalence of diabetes and the limited cadaveric organ 
donor pool [37]. Also, the risks associated with islet transplantation appear to increase with the 
number of infusions and with the total packed cell volume of cumulative grafts [42]. Islet 
function and wellbeing are already undermined by stressful events before transplantation [43, 
44]. Donor characteristics such as medical history, glucose control, age, length of hospitalization, 
and cause of death have a significant impact on islet recovery after isolation [43]. During 
pancreas procurement and preservation, islets are exposed to warm and cold ischemia that may 
impair survival and eventually contribute to graft failure after transplantation [45, 46].  
The isolation process is designed to remove the exocrine part of the organ while preserving 
structurally intact islets [47]. During isolation and purification, islets are exposed to mechanical, 
enzymatic, osmotic, and ischemic stresses, so a large proportion of islets can be either 
compromised or destroyed [48, 49]. Islet isolation triggers a cascade of events leading to 
apoptosis, necrosis and the production of proinflammatory molecules, which reduces islet yield 
and affects islet functioning after transplantation [50]. Oxidative stress plays a major role in 
triggering the death of islets and surrounding exocrine tissue during isolation [51]. Islet beta-cells 
are highly susceptible to oxidative stress because of their reduced levels of endogenous 
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antioxidants [52‐54]. Under conditions of stress, the islet antioxidant systems may become 
depleted, leading to a state of redox imbalance and the production of reactive oxygen species 
(ROS). Isolation not only disrupts the internal vascularization and innervation of islets, but also 
fundamentally changes interactions between islet cells and macromolecules of the extracellular 
matrix (ECM). Signaling interactions between islet cells and ECM are known to regulate 
multiple aspects of islet physiology, including survival, proliferation, and insulin secretion [55]. 
During isolation, loss of islets occurs to some extent due to the activation of an anoikis-type 
mechanism evoked by disruption of the surrounding ECM [44, 56]. Cells disrupted from their 
ECM display a loss of transmembrane integrin signaling [57]. Evidence suggests that the beta-
cell phenotype is fragile and easily lost upon removal of these cells from their native 
environment [58, 59]. The beta-cell specific transcriptional network is affected during the 
isolation process, and in vitro culture further induces de-differentiation of mature beta cells 
towards pancreatic progenitor cell stage [60, 61]. 
Early graft failure remains an important clinical problem in intraportal islet transplantation. 
Pancreatic islets are highly vulnerable during the immediate post-transplantation period. 
Experimental studies demonstrate that the most marked decrease in the islet cell mass takes place 
in the first 15 days after islet transplantation and persists even after revascularization has 
occurred [62, 63]. Post-transplantation metabolic data suggest that 25-75% of the islets fail to 
engraft, increasing the number of islets required to achieve initial normoglycemia after 
transplantation [34, 35]. Experimental models of syngeneic islet transplantation demonstrated 
that 60% of transplanted islet tissue was lost 3 days after transplantation due to necrosis and 
apoptosis [64], suggesting the involvement of nonalloantigen-specific, inflammatory events in 
partial destruction of the graft [65]. The rate of apoptosis following islet transplantation is 10 
times higher than the rate seen in the native pancreatic islets [64]. 
The loss of islets during the immediate post-transplantation period is mainly due to 
inflammatory events, which occur before adaptive immunity initiates rejection. These include the 
activation of platelets, coagulation and complement systems, generation of cytokines and free 
radicals, recruitment of immune cells and induction of the stress response. Innate immunity and 
heat shock response are believed to be among the most important factors that can affect the early 
islet loss. The main functions of innate immunity include initiation of instant defensive reaction 
against foreign objects and antigen presentation [64, 66, 67].  
An important mediator of inflammation in the hepatic sinusoids is the Kupffer cell, which is 
the resident macrophage of the liver [68]. When activated, Kupffer cells release free radicals and 
secrete inflammatory cytokines [69]. During stress and hypoxia islets can produce and release 
cytokines that attract and activate macrophages [70‐72]. In addition, Kupffer cells can be 
activated by ischemia-reperfusion injury to the sinusoidal endothelial cells [73] and the liver 
parenchyma [74]. When transplanted along with pancreatic islets, acinar tissue undergoes 
necrosis [75], which can also contribute to Kupffer cells activation [65].  
Upon injection into the recipient, direct exposure of human islets to blood triggers instant 
blood-mediated inflammatory reaction (IBMIR), characterized by activation of coagulation and 
complement systems, platelet aggregation, and infiltration of islets with neutrophils and 
monocytes [76‐80]. IBMIR ultimately results in lysis of islet cells [81,82].  
Another reason for graft failure is the absence of established vasculature, which is normally 
destroyed during the isolation process [63, 83]. The islets of Langerhans constitute 1-2% of 
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pancreas mass. However, they receive 10-20% of pancreatic arteriolar flow, demonstrating a 
significant need for oxygen and nutrients for immediate insulin secretion in response to glucose 
stimulation [84, 85]. During the first several weeks post-transplantation, the pancreatic islets are 
exposed only to portal venous blood [86]. The essential nutrients and oxygen can only be 
supplied through diffusion from the surrounding tissues into the transplanted islets [87-89]. The 
time required for revascularization of transplanted islets is approximately two weeks [90‐92]; 
therefore, hypoxia is a serious contributor to islet loss in the early post-transplant period [93]. 
Although tissue ischemia alone may be deleterious, the reintroduction of oxygen after 
reperfusion is more harmful [94]. Molecular oxygen is the source of reactive oxygen metabolites, 
which are responsible for the majority of the tissue damage seen during the sequence of ischemia 
and reperfusion [95, 96].  
Alloreactive T-cell-mediated graft rejection of pancreatic islets presents the major challenge in 
transplantation. A substantial fraction of islet transplants undergo chronic failure due to immune 
rejection, despite the use of modern immunosuppressive agents [97, 98]. Rejection is initiated 
when recipient CD4+ T cells detect donor antigens derived from a highly polymorphic region of 
the genome called the major histocompatibility complex (MHC). Activated CD4+ T cells 
contribute to the rejection process by secreting lymphokines and stimulating macrophages, CD8+ 
cytotoxic T cells and alloantibody-producing B cells [99]. 
There is also considerable evidence that immunosuppressive drugs used to prevent graft 
rejection have deleterious effects on beta-cell survival and/or function [100]. FK506 (tacrolimus) 
can inhibit glucose-stimulated insulin release and beta-cell regeneration [101]. Rapamycin 
(sirolimus) has been shown to have deleterious effects on beta-cell function and growth [102]. 
Mycophenolate mofetil (MMF) inhibits insulin secretion from islets and can induce apoptosis in 
beta-cells [101].  
Furthermore, the grafted islets are also exposed to the autoimmune process that initiated the 
original disease. Pathogenic T cells and autoantibodies preexist in T1DM patients; therefore, 
islets transplanted to a recipient with T1DM represent a cellular transplant to a pre-sensitized 
host [103]. Progressive islet graft failure occurs significantly earlier in autoantibody-positive 
than in autoantibody-negative T1DM recipients of intrahepatic islet allografts [104]. 
Strong experimental evidence indicates that constant exposure of pancreatic islets to high 
glucose results in impaired glucose-stimulated insulin secretion and beta-cell damage [105], 
[106‐111]. Animal studies have demonstrated that severe hyperglycemia impairs graft function, 
and that successful islet transplantation depends on the degree of hyperglycemia in the recipient 
[62, 112‐117]. Labile blood sugars and chronic hyperglycemia may drive a systemic 
inflammatory response that creates an environment hostile to islet engraftment [117‐119]. An 
elevated level of apoptosis was shown in pancreatic islets exposed to chronic hyperglycemia 
immediately after transplantation [64]. 
Despite the challenges listed above, the majority of recipients of pancreatic island grafts 
benefit from a reduced overall insulin requirements, improved C-peptide secretion and HbA1C 
levels, a fewer microvascular complications, and a fewer complications related to episodes of 
hypoglycemia after 5-year follow up [120]. 
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4.4 Monitoring of the Islet Graft 
Regardless of the islet damage pathway, there is a need to monitor surviving grafts in diabetic 
patients. There is no agreement on the best ways to assess islet graft function. The current 
clinical trials rely on metabolic monitoring of the islet graft. Overall function of transplanted 
islets is evaluated by measurements of plasma glucose, insulin, C-peptide, HbA1c, fructosamine 
levels, insulin requirement, and by calculations of the secretory unit of islet transplant objects 
and the beta-score. Blood glucose stability is reflected by mean amplitude of glycemic 
excursions, lability index and continuous glucose monitoring systems. Islet response to a 
standardized stimulus is assessed by an arginine stimulation test, a glucagon stimulation test, a 
mixed meal tolerance test, an oral glucose tolerance test, an intravenous glucose tolerance test, 
and a glucose-potentiated arginine stimulation test [121]. Metabolic tests are time consuming and 
cumbersome to perform; their use is limited to selected time points during the follow-up. 
Therefore, they detect graft dysfunction when a substantial islet mass has been already lost, 
preventing timely rescue interventions [122]. At most institutions, routine abdominal color 
Doppler ultrasound is performed at the time of the procedure, in the early postoperative period, 
and annually thereafter to allow detection of complications such as hemorrhage, portal vein 
thrombosis, periportal hepatic steatosis, and the presence of ischemic/necrotic regions in the 
recipient’s liver [26]. Computerized tomography (CT) and MRI have also been used to detect 
intrahepatic posttransplant structural changes [123-125]. None of these imaging modalities 
visualize the graft directly, and various processes, including excess glycogen accumulation, 
edema and inflammation can affect their results. The association between graft function and liver 
steatosis was highly controversial because despite the presence of steatosis, graft function at the 
time of imaging was not compromised [126]. The only direct functional assessment of transplant 
fate currently available is performed through liver biopsy, which is an invasive procedure with 
several complications [127]. Moreover, the quantity of islets engrafted in the liver is very low 
and percutaneous needle biopsies have low chances of sampling islets, unless multiple biopsies 
are performed [121]. Development of new, non-invasive methods to determine islet graft 
function and the beta cell mass over time will be particularly helpful for the monitoring of islet 
engraftment, islet cell plasticity, and functionality after transplantation. They may also be helpful 
for guiding timely interventions to prevent loss of the islet mass [122]. 
Molecular imaging is a rapidly developing biomedical research discipline, which utilizes 
specific molecular probes as the source of image contrast [128, 129]. Extensive research has 
been done towards the development of noninvasive, high- resolution in vivo imaging 
technologies including optical imaging, nuclear imaging, and MRI. Isolated islets can be labeled 
before transplantation using various approaches, including genetic modification with fluorescent 
or bioluminescent reporters for optical imaging, labeling with exogenous contrast agents, such as 
superparamagnetic iron oxides for MRI, or radiolabeled metabolites for nuclear imaging [130]. 
The small islet size (50–300 μm) and large distribution area in the liver make noninvasive islet 
imaging very challenging. In order to detect a single islet in the liver, the imaging modality 
should have high resolution and/or employ a specific islet- or beta-cell labeling technique. 
Furthermore, the decrease of signal intensity must be observed earlier than the alteration of the 
usual graft function parameters, so the graft could be saved in the case of allograft rejection. 
Finally, to be approved for human clinical practice, an imaging technique must be safe both for 
the recipients and the islet graft [131]. 
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The first animal studies of the noninvasive imaging of transplanted islets utilized the 
bioluminescence (BLI) optical imaging modality [132‐136]. In vivo optical imaging uses light as 
a source of contrast. Bioluminescent cells are modified to express the luciferase enzyme gene, 
either after in vitro islet transfection with a viral vector [134], or by generating transgenic mouse 
strains expressing the luciferase gene under the regulation of the insulin promoter [137]. 
Luciferase expression does not adversely affect islet metabolic function [134, 137]. For imaging, 
the luciferase substrate, injected just before the image acquisition, is oxidized by luciferase in 
luciferase-expressing cells in an oxygen- and ATP- dependent manner [131]. The product of the 
reaction emits light that can be detected by a cooled charge-coupled device and quantified in vivo 
for at least 18 months [138]. There is a linear relationship between the amount of islets 
transplanted and the intensity of the luminescent signals detected [134]; however, the resolution 
of the signal is low and does not allow detection of single islets scattered throughout the liver 
[139]. Remarkably, luminescence intensity started to decrease several days before permanent 
recurrence of diabetes and histologically demonstrated acute rejection in an allogeneic model 
[138]. As a drawback, the light attenuates very strongly when it propagates through the tissue 
before reaching the detector; for that reason BLI can only be used as a research tool in mice 
[129, 131]. 
Fluorescence optical imaging employs fluorophores, which re-emit light when stimulated with 
light of the appropriate wavelength. A cooled charge-coupled device collects emission light from 
fluorophore-labeled molecules of interest distributed in biological systems. The fluorescent 
proteins can be visualized in both live and fixed cells/tissues, and no substrate is required for 
their visualization. Certain disadvantages include difficulties in quantitation, as well as the 
surface-weighted nature of the image in which objects closer to the surface will appear brighter 
than deeper structures [140]. Fluorescence optical imaging has been used for the monitoring of 
immunological effects associated with islet transplantation at cellular level. Bertera et al. 
engineered a transgenic mouse expressing proinsulin II tagged with a live-cell fluorescent 
reporter protein, Timer. The Timer protein has ability to change color from green to red in the 
first 24 h after synthesis. With this marker, insulin synthesis can be monitored with a confocal 
microscope through the changes in fluorescence over time. Islets expressing the Timer protein 
were transplanted under the kidney capsule of the recipient mice, and a body window device was 
inserted to monitor beta cells and migrating to the islets T cells labeled with a fluorochrome 
distinguishable from the Timer protein [141]. Recently, Fan et al. established methods to 
longitudinally track islet allograft-infiltrating T cells in live mice by endoscopic confocal 
microscopy and to analyze circulating T cells by in vivo flow cytometry. A new reporter mouse 
model was developed, whose T cell subsets express distinct, ‘color-coded’ proteins enabling in 
vivo detection of different T-cell subsets. Marked differences were observed in the T cell 
response in islet grafts recipients receiving tolerance-inducing treatment compared to control 
group [142]. These studies established a real-time cell-tracking tool for monitoring islet graft 
rejection, but they lack an equivalent applicable to human studies, thus preventing their direct 
translation to clinical use. 
Positron emission tomography (PET) is a nuclear imaging technique that provides high 
resolution, good sensitivity, and accurate quantification of physiologic, biochemical, and 
pharmacologic processes in living subjects [131]. For the last decade PET has been employed for 
pre-clinical and clinical imaging of islet transplantation. PET imaging utilizes positron-emitting 
radioisotopes (tracers) as labels. Radioactive probe, containing a biologically active molecules 
tagged with a tracer, can be introduced into the subject and then PET imaging can follow their 
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distribution and concentration over time [143]. Large animal [144] and clinical [145, 146] 
studies on hepatic grafts employed the commonly used 18F-fluorodeoxyglucose (18F-FDG) 
probe for pre-transplant labeling of isolated islets. 18F-FDG enters the cell by the same 
transporters as glucose and is rapidly phosphorylated ensuring high intracellular retention [147]. 
Following intraportal infusion 18F-FDG-labeled islets appeared as multiple “hot spots” 
heterogeneously distributed throughout the liver. On average, only 63% of the administered 
radioactivity was detected in the liver, suggesting that considerable amount of transplanted islet 
cells were damaged to the extent that the 18F-FDG they contained was released during the first 
few minutes after transplantation. A parallel, marked increase in plasma C peptide was observed, 
also indicating islet destruction presumably due to IBMIR. Clinical outcome in all patients was 
comparable to that previously observed indicating that the 18F-FDG labeling procedure did not 
harm the islets [145, 146]. However, because of the short half-life of 18F (109.8 min), this 
technique can be used only to study islet survival and engraftment immediately after islet 
infusion. If the same technique could be used with an isotope with markedly longer radioactive 
half time to allow imaging over several days to weeks, possible damaging radiation effects on the 
islets would have to be investigated in further detail before clinical use [146]. Another type of 
PET tracer 18F-FHBG has been used for tracking mouse islets transfected with a mutant form of 
the gene encoding for herpes simplex virus 1 thymidine kinase (HSV1-sr39tk) in a series of 
studies [148‐151]. 18F-FHBG accumulations at the transplantation sites were linearly correlated 
with the size of the engineered graft. However, tracer uptake at the graft site declined over the 
following several weeks, which was partially related to the transient nature of adenovirus-
directed gene expression. Genetic engineering of islets prior to administration can be damaging, 
and development of safer and more controllable gene transfer systems may be required before 
translation into clinical islet transplantation [152]. A novel PET probe 64Cu-DO3A-VS-Cys40-
Exendin-4 targeting glucagon-like peptide 1 receptor (GLP-1R) on beta-cells has been tested for 
detecting of human islets transplanted into the mice liver [153]. Ten days after transplantation, 
liver uptake of the radiotracer was significantly higher in transplanted mice than in control mice. 
Further studies are needed to test the feasibility of long-term monitoring of transplanted islets 
with 64Cu-DO3A-VS-Cys40- Exendin-4. 
Magnetic resonance imaging is one of the most reasonable modalities to explore for tracking 
of pancreatic islets following transplantation. MRI does not utilize ionizing radiation, has 
tomographic capabilities, can deliver the highest-resolution images in vivo, and has unlimited 
depth penetration. Tissue contrast in MR images reflects the differential distribution of hydrogen 
(1H) atoms in particular tissues. As hydrogen atoms (protons) are mainly found within water 
molecules, MRI scans essentially visualize the distribution of water molecules in different types 
of tissues. This relative distribution varies among tissues, and there are other macromolecules 
(i.e., proteins) that can contain bound water in various amounts. In addition, protons can be 
found in chemically distinct substances, such as lipids (e.g. myelin and adipose tissue), and 
paramagnetic endogenous tissue iron can also be found in certain tissues. All these factors 
determine contrast between tissues [154]. MRI is routinely used for the morphologic evaluation 
of structural changes in the liver after islet transplantation [126]. However, this method has not 
been reported to be able to visualize native or transplanted pancreatic islets, most likely because 
their magnetic properties are similar to the surrounding tissue. Therefore, a contrast agent must 
be applied in order to visualize islets on MR images.  
Superparamagnetic iron oxide nanoparticles have been extensively used as magnetic resonance 
reporters for detecting pathologies in different organs [155]. The basic structure of these 
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nanoparticles includes an iron oxide core covered with a dextran coat [156] that can be further 
modified depending on the need of the specific study. Nanoparticle presence in tissue is evident 
primarily by a darkening effect on T2-weighted MR images. Remarkably, the T2* effect of 
superparamagnetic iron oxides results in a hypointensity footprint many times larger than the 
labeled entity, in essence constituting a powerful signal amplification tool. With its high spatial 
resolution and the fact that physiologic and anatomic information can be extracted 
simultaneously, MRI is now capable of providing high-resolution images (on the order of tens of 
microns per voxel resolution) of nanoparticle disposition in vivo, both in small animals and in 
humans [157]. Our laboratory pioneered studies on imaging of the diabetic pancreas including 
imaging of autoimmune attack ex vivo [158] and in vivo [159], imaging of beta-cell mass [160] 
and beta-cell death [161]. Taking into account its importance and potential clinical use in the 
near future, in vivo magnetic resonance imaging of pancreatic islet transplantation has been one 
of the major directions of our research. 
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5. Aims of the Thesis 
 
The main objective of this work was to develop and evaluate a method to non-invasively 
detect human pancreatic islets, labeled with an MRI contrast agent, and transplanted into diabetic 
animals. 
 
The specific aims were to investigate: 
 
 whether human pancreatic islets could be labeled with a magnetic imaging probe that would 
produce a sufficient signal-intensity change on magnetic resonance images without altering 
islet insulin-producing function 
 whether labeled islets can be monitored in vivo by MRI noninvasively and repeatedly in real 
time 
 whether the relative transplanted islet mass can be quantified and tracked over time by MRI 
 whether MRI can monitor islet death due to immune rejection or glucose toxicity 
noninvasively and repeatedly in real time. 
 whether islet purity has any effect on labeling by a magnetic imaging probe 




6. Materials, Methods, and Results 
 
6.1 Paper I and Paper II (Methods only). In Vivo Imaging of 
Pancreatic Islet Transplantation 
 
Study design: Human pancreatic islets labeled with magnetic nanoparticles modified with 
the near-infrared fluorescent Cy5.5 dye (MN-NIRF) 
 





Part 1. In Vitro Islet Analysis 
Labeling of isolated 




infrared channel) of 
isolated islets 
All islets in the field of view appeared to be 
labeled with the probe (Fig. 1a). Control 
unlabeled islets did not have any signal. 
Magnetic resonance 
imaging of labeled islets 
 
MRI 9.4T of islet 
phantoms 
Labeled islets caused a marked decay in tissue 
transverse magnetization (T2/T2* effect) on 
MRI. The signal intensity of labeled islets 
decreased compared to unlabeled islets, and 
these labeled islets appeared hypointense (dark) 
as a result of MN-NIRF accumulation (Fig. 1b) 
Correlation between 
number of islets and 
change in T2/T2* 
relaxivity 
MRI 9.4T of islet 
phantoms 
There was a direct linear correlation between 
T2* values and number of labeled islets (Fig. 
1c). 
Iron uptake per islet cell 
after incubation with 
increasing 
concentrations of the 
MN-NIRF probe 
Total Iron Reagent 
Set 
 
Iron uptake by the islets varied from 2.26 ± 
0.53 to 12.17 ± 0.97 pg iron/cell (Fig. 1d) 
(assuming 2,000 cells/islet). 
Staining of labeled islet 





The majority of Cy5.5 in the islet cells was 
associated with intracellular endosomal 
staining, indicating its intracellular localization 
(Fig. 1e, Supplementary Fig. 1). 





Confirmed the intracellular localization of the 
probe linked to endosomal structures 
(Supplementary Fig. 2). 
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Staining of labeled 








The Cy5.5 signal colocalized mainly with 
insulin-specific staining, suggesting that the 
majority of the MN-NIRF probe associated 
with beta cells (Fig. 1f).  
Insulin secretion by 
labeled islets 
ELISA Labeling with MN-NIRF does not affect 
islet insulin function. 
Viability of labeled 
islets 
MTT Islet viability remained unchanged. 
Part 2. MN-NIR-Labeled and Unlabeled Islets Transplanted under the Left and Right Kidney 
Capsule of Healthy Nude (nu/nu) Mice 
Feasibility of magnetic 
resonance imaging of 
islets in vivo 
MRI 4.7T Decrease in signal intensity on T2* MRI 
images at the implantation site of labeled 
islets was observed up to 188 days (Fig. 2a). 
Analysis of T2 maps showed a significant 
difference in T2 relaxation times between 
labeled and unlabeled grafts for the duration 
of the experiment (Fig. 2b and 
Supplementary Fig. 3). 
Detection threshold of 
magnetic resonance 
imaging of islets in vivo 
MRI 4.7T The T2 relaxativity depended on the number 
of transplanted islets. There was a direct 
linear correlation between the number of 
islets in the graft and graft volume (Fig. 2c). 
In vivo imaging of the 
labeled islet graft 
Near-infrared optical 
imaging of the mouse 
A bright fluorescent signal at the 
transplantation site indicated the presence of 
labeled islets in the kidney (Fig. 3a). 




Imaging confirmed the presence of 
fluorescent signal coming from the labeled 
graft and the absence of fluorescence in the 
unlabeled graft (Fig. 3b). 
Staining of the graft 




Confocal microscopy Colocalization of the probe with endosomes 
indicated that after transplantation the probe 
maintained its intracellular localization 
within the graft after in vitro labeling (Fig. 
3d and Supplementary Fig. 6). 
Staining of the graft 




Pancreatic islets within the graft maintained 
their ability to secrete insulin 188 d after 
transplantation (Fig. 3e). 
Staining of the graft 
sections for apoptosis 
TUNEL assay The amount of apoptosis in the graft 188 
days after transplantation was negligible 
(Fig. 3f). No evidence of massive islet cell 
death that could result in the release of 
substantial amounts of iron, which would 
create 'false-positive' T2 measurements. 
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Part 3. MN-NIRF-Labeled and Unlabeled Islets Transplanted Under the Kidney Capsule in 






Seven to ten days after transplantation, mice 
became euglycemic for the duration of the 
experiment. There was no difference in 
achieving normoglycemia between mice 
transplanted with labeled and unlabeled 
islets.  
In vivo imaging of 
labeled islets 
MRI 4.7T Considerable darkening was observed at the 
site of labeled islet transplantation in the 
kidney (Fig. 2d). T2 maps confirmed that 
the nature of the signal observed in the 
kidney owed to the presence of the labeled 
graft (Supplementary Fig. 4). 




A bright fluorescent signal at the 
transplantation site indicated the presence of 
labeled islets in the kidney (Supplementary 
Fig. 5). 
Ex vivo imaging of 
excised kidney cross-
sections. 
MRI and optical 
imaging 
Confirmed that the signals obtained with 
both modalities originated exclusively from 
the graft (Fig. 3c). 
Part 4. MN-NIRF–Labeled and Unlabeled Islets Transplanted Intraportally in Streptozotocin-
Treated Nonobese Diabetic–Severe Combined Immunodeficient (NOD-SCID) Mice 
Feasibility of in vivo 
imaging of labeled 
islets  
MRI 4.7T Labeled islets appeared as dark hypointense 
spots representing single islets and/or islet 




transplanted islets  
MRI 4.7T Labeled islets were readily visible for the 
duration of the experiment. The overall 
associated T2* values increased somewhat 
and then reached a plateau over time (Fig. 
4a), possibly indicating islet loss in this 





Normoglycemia in diabetic mice 
transplanted with labeled or unlabeled islets 
was restored within 1 week. 




Bright foci represented transplanted islets 
and thus confirmed the presence of the 
probe in the graft (Supplementary Fig. 7). 
Correlative microscopy 
of liver sections (H&E, 
Cy5.5, insulin). 
Bright light and 
fluorescence 
microscopy 
Studies confirmed the presence of labeled 
islets in the liver and their ability to secrete 





 Human pancreatic islets can be labeled by superparamagnetic iron oxide nanoparticles 
(MN-NIRF) 
 
 Labeling of human pancreatic islets with MN-NIRF does not adversely affect islet 
viability and function 
 
 The MN-NIRF-labeled pancreatic islets transplanted under the mouse kidney capsule or 
into the mouse liver appear as dark hypointense foci representing islet clusters and/or 
single islets on T2*-weighted images 
 
 There is a direct linear correlation between T2* values and a number of the labeled islets 
 
 MRI can be used to monitor labeled pancreatic islets in vivo noninvasively and repeatedly 
in real time 
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6.2 Paper III. In Vivo Imaging of Immune Rejection in 
Transplanted Pancreatic Islets 
 
Study design: Human pancreatic islets labeled with the FDA-approved, commercially 
available superparamagnetic iron oxide nanoparticle-based contrast agent Feridex 
(ferumoxide). 
 





Part 1. In Vitro Islet Analysis 
Iron uptake per islet cell 




Total Iron Reagent 
Set 
Iron uptake by the islets varied from 1.21 ± 
0.36 to 18.26 ± 1.36 pg iron/islet cell, 
(assuming 2,000 cells/islet) (Fig. 1B). 
Time course study of 
iron uptake by the islets 
Total Iron Reagent 
Set 
There was an increase in the islet iron 
content with increasing incubation time, with 
a maximum at 12 h (Fig. 1C). 
Feridex retention by the 
islets 
Total Iron Reagent 
Set 
The iron content of islets remained constant 
after incubation in Feridex-free culture for up 
to 24 h (Fig. 1D). 
Amount of Feridex 
accumulated in islets 
Prussian Blue stain 
and Light microscopy 
The accumulation of Feridex in islets varied 
from 10 to 70% (Fig. 2B). 
Feridex distribution in 
islet cells: islets were 
stained for insulin, 
glucagon, somatostatin, 
macrophages and iron 
Immunohistoche-
mistry, Prussian Blue 
stain and light 
microscopy 
 
Feridex colocalized with insulin-producing 
beta-cells andm, to a lesser degree, with 
delta, alfa cells and resident macrophages 
(Fig. 2A). 
Insulin secretion and 
viability of Feridex-
labeled islets 
ELIZA and MTT Insulin secretion and islet viability after 
exposure to Feridex remained unchanged. 
Magnetic resonance 
imaging of labeled islets 
MRI 9.4T of islet 
phantoms 
Labeled islets produced a decrease in signal 
intensity on T2-weighted images (Fig. 1A). 
 
Part 2. Feridex-Labeled Islets Transplanted Intraportally in Severe Combined 
Immunodeficient (NOD-SCID) and Immunocompetent (Balb/C) mice. Control Animals 
Transplanted with Unlabeled Islets. 
In vivo imaging of 
transplanted islets 
MRI 4.7T Islets transplanted into the liver appeared as 
dark hypointense foci representing single 
islets and/or, possibly, islet clusters (Fig. 
3A), whereas unlabeled islets did not cause 
any change in signal intensity on T2*-
weighted images (Fig. 3B). 
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Analysis of the relative 
transplanted islet mass 
on MR images 
Validation of the 




Manually scoring of 
the signal voids on 
MR images 
The known number of transplanted islets 
directly correlated to the number of dark 
voids representing labeled islets/islet clusters 
found on T2*-weighted images (Fig. 3D). 
Visual co-registration of 





MRI 4.7T Disappearance of signal voids in Balb/c mice 
was more pronounced than in NOD.scid 
mice over time (Fig. 3C). 






The number of signal 
voids on MR images 
was scored manually 
Immunocompetent mice exhibited a 
significantly higher rate of islet 
disappearance compared with 
immunocompromised animals, especially 
pronounced on day 10, and resulting in a 
20% difference in islet number by 14 days 
after transplantation (Fig. 3E). 
Part 3. Livers from the Animals Excised on Each Day of Imaging and Used for Ex Vivo 
Studies. 
Immune rejection of 
transplanted islets.  









mistry and light 
microscopy 
 
Infiltration of the graft by CD68, CD4, CD8, 
CD19 positive cells and neutrophils in Balb/c 
mice started on the first day after 
transplantation (Table 2, Fig. 4A). The level 
of infiltration by these cells increased with 
time and peaked on days 10-11 in agreement 
with the TUNEL assay results. In contrast, 
NOD.scid mice showed only marginal 
presence of immune cells in islets after 
transplantation except for CD68 positive 
invading macrophages (Fig. 4B).  
Apoptosis rate in 
transplanted islets 




In NOD.scid and Balb/c mice apoptosis was 
most pronounced on day 1. The number of 
apoptotic cells in immune-deficient mice 
decreased to 1.8% by day 4 and stayed at this 
level for the duration of the study. In 
contrast, the number of apoptotic cells in 
immunocompetent mice gradually decreased 
to 3.3% on days 4-5 followed by severe 
antigen-specific rejection, which destroyed 
up to 13.2% of the islets on days 10-11 (Fig. 
3E). The apoptosis level gradually decreased 
by day 14 since by that time, almost all cells 
in the islets were destroyed. 
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Fate of Feridex in 
transplanted islets after 
islet death 
Prussian Blue stain 
and Light microscopy 
 
After death islets released Feridex into the 
liver parenchyma where it was internalized 




 Human pancreatic islets can be labeled with the Food and Drug Administration–
approved, commercially available contrast agent Feridex 
 
 Labeling of human pancreatic islets with Feridex does not adversely affect islet viability 
and function 
 
 The Feridex-labeled islets transplanted into the mouse liver appear as dark hypointense 
foci representing single islets and/or islet clusters on T2*-weighted images 
 
 In the mouse transplantation model, the relative transplanted islet mass can be quantified 
by manually scoring the number of hypointense voxels representing islet graft on MR 
images. The islet mass value can be tracked over time 
 




6.3 Paper IV. Effects of Glucose Toxicity and Islet Purity on In 
Vivo Magnetic Resonance Imaging of Transplanted Pancreatic 
Islets 
 
Study design: Human pancreatic islets labeled with the FDA-approved, commercially 
available superparamagnetic iron oxide nanoparticle-based contrast agent Feridex 
(ferumoxide). 
Aims / Details of the 
Study 
Imaging Modality / 
Assay 
Main Results 
Part 1. Islets of 20% and 98% Purity Labeled with Feridex 
Iron uptake by islets 
expressed as iron-to-
protein ratio  
Total Iron Reagent 
kit / Protein assay 
Iron uptake was significantly higher in high-
purity islets than in low-purity islets (Fig. 
3A). 
Part 2. Pure Islets and Non-endocrine Tissue Labeled with Feridex 
Imaging of Feridex-
labeled and unlabeled 
high-purity islets, non-
endocrine tissue and 
islets mixed with non-
endocrine tissue. 
MRI 9.4T of cell 
phantoms 
Labeled islets had T2 values significantly 
lower than the labeled non-endocrine tissue 
and a 67%/33% mixture of labeled islets and 
non-endocrine cells. 
Part 3. Feridex-Labeled Islets of 95% and 50% Purity Transplanted Intraportally in Healthy 
and Severe Combined Immunodeficient (NOD-SCID) Mice 
In vivo magnetic 
resonance imaging of 
transplanted islets of 
different purity 
MRI 4.7T Visually, the number of dark spots 
representing labeled islets appeared to be the 
same (Fig. 4A,B). 
Quantitative analysis of 
islet loss on MR images 
MRI 4.7T The two groups of animals did not exhibit 
any statistically significant difference in islet 
disappearance rate throughout the study (Fig. 
5A). 
Ex vivo analysis of 
apoptosis rate in 
transplanted islets 
 




Graft cell death on day 2 was 4.2-fold higher 
in mice transplanted with 50% purity islets 
than in mice transplanted with 95% purity 
islets (Fig. 5B). 
Ex vivo analysis of graft-
bearing livers for acinar 
and ductal elements 
Immunohisto-
chemistry and light 
microscopy 
Non-endocrine tissue was detectable in both 
groups of animals on day 2, but was higher in 
quantity in 50% purity islet grafts (Table 1). 
The disappearance of acinar and ductal 
elements was more pronounced in the grafts 
of 50% purity. 
Macrophage infiltration 
of islets grafts 
Immunohisto-
chemistry and light 
microscopy 
Macrophage infiltration was significantly 
higher on days 6 and 15 in the 50% purity 
grafts contaminated with non-endocrine 
tissue (Fig. 5C). 
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Part 4. Feridex-Labeled Islets Transplanted Intraportally in Healthy and Diabetic Severe 
Combined Immunodeficient (NOD-SCID) Mice 
MR imaging of healthy 
and diabetic mice 
transplanted with 
Feridex-labeled islets 
MRI 4.7T There was a visual difference in number of 
islets between the groups on day 5 after 
transplantation (Fig. 1A,B). 
Quantitative analysis of 
the number of 
transplanted islets in 




Half-life of the islets in diabetic mice was on 
average 2.6 times shorter than in healthy 
animal (Fig. 2A). 
Glucose homeostasis  Glucometer Before islet transplantation, blood glucose 
values were more than sevenfold higher in 
diabetic mice than in healthy animals (Fig. 
2B). Diabetic mice became normoglycemic 
on day 10. 
Correlation between the 




Pearson correlation In diabetic animals, newly transplanted islets 
experience glucotoxic stress (on Fig. 2C 
points with high glucose levels and high 
number of newly transplanted islets). Some 
islets died. Islets that survived restored 
normoglycemia (points with low glucose 
levels and low islet number). In the control 
animals, glucose levels stayed normal and 
had no influence on islet survival. 
Ex vivo analysis of 
apoptosis rate in 
transplanted islets 




The apoptotic rate was higher in diabetic 




 MRI can monitor pancreatic islet death due to glucose toxicity noninvasively and 
repeatedly in real time 
 
 Transplantation of pancreatic islets contaminated with non-endocrine tissue does not have 
any significant influence on MR images, presumably because of a low labeling rate of 
this tissue and a fast rate of its disappearance after transplantation 
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6.4 Paper V. In Vivo Imaging of Autologous Islet Grafts in the 
Liver and Under the Kidney Capsule in Non-Human Primates 
 
Study design: Baboon pancreatic islets labeled with the Food and Drug Administration-
approved superparamagnetic iron oxide contrast agent Feridex (ferumoxide). 





Part 1. In Vitro Islet Analysis 
Insulin secretion ELISA Glucose-stimulated insulin release was 
unchanged in labeled versus unlabeled islets 
(Fig. 1C). 
Iron retention assay Total Iron Reagent 
Set 
The iron content of baboon islets remained 
constant after incubation in a Feridex-free 
culture for 24 hr (Fig. 1A). 
Apoptosis assay Fluorometric 
caspase-3 assay 
Labeling islets with Feridex did not increase 
the apoptotic rate in labeled compared with 
unlabeled islets (Fig. 1B). 
Part 2. After a Partial Pancreatectomy, Feridex-Labeled Islets Autotransplanted Underneath 
the Renal Capsule and into the Liver of a Baboon (Papio hamadryas) 
MR imaging of islets 
transplanted under the 
kidney capsule 
MRI 1.5T On T2*-weighted MR images, islets appeared 
as a pocket of signal loss disrupting the contour 
of the kidney (Fig. 2A). Signal coming from 
the graft was detectable throughout the follow-
up period. 
MR imaging of islets 
transplanted 
intrahepatically 
MRI 1.5T On T2*-weighted MR images, islets appeared 
as distinct areas of signal loss, seen as signal 
voids dispersed throughout the liver (Fig. 2B). 
Signals coming from the islets were detectable 
throughout the follow-up period. 
Development of a 
semiautomated image 
segmentation algorithm 
for analysis of the 




(based on MatLab) 
The kidney and the liver were each classified 
into two labels based on their T2* values: the 
islet graft label and the renal parenchyma (Fig. 
3A), or the islet graft label and the liver 
parenchyma (Fig. 3B). The T2* values 
associated with the two labels were sufficiently 
distinct to allow precise differentiation 
between the two in both the kidney and the 




of relative transplanted 






There was a relative stability in the islet mass 
transplanted underneath the renal capsule 
during the initial (30 days) posttransplant 
period (Fig. 4A). In the intrahepatic model, 
there was a noticeable 25% decrease in 
transplanted islet mass between days 3 and 8 
after transplantation. This was followed by 
stabilization of the graft over the observation 
period (Fig. 4B). 








blood urea nitrogen 
and creatinine 
During the follow-up the animals showed no 
signs of infection, anemia (Fig. 5A) or 
symptoms of systemic inflammation. They 
maintained normal weight gain and protein 
metabolism. The changes in triglycerides and 
cholesterol levels were transient and associated 
with the surgical transplantation procedure, 
with normalization thereafter (Fig. 5B). 
Besides a transient increase in the levels of 
aspartate aminotransferase, alanine 
aminotransferase, and bilirubin after the partial 
pancreatectomy, the liver function tests 
indicated no effects on hepatic physiology 
(Fig. 5C). Blood urea nitrogen and creatinine 
values remained within normal range during 
the follow-up period suggesting normal renal 
function (Fig. 5D). 
Long-term functionality 







Fasting blood glucose (Fig. 6A) and 
intravenous glucose tolerance (Fig. 6B) 
remained normal and unchanged before and 
after completion pancreatectomy, indicating 
that the labeled grafts were sufficient to 




 Baboon pancreatic islets can be labeled by the Food and Drug Administration–approved, 
commercially available contrast agent Feridex 
 
 Labeling of baboon pancreatic islets with Feridex does not adversely affect islet viability 
and function 
 
 On T2*-weighted MR images, pancreatic islets transplanted underneath the renal capsule 
appear as an area of signal loss 
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 On T2*-weighted MR images, pancreatic islets transplanted intrahepatically appear as 
distinct areas of signal loss, seen as signal voids dispersed throughout the liver 
 
 Low-field clinical MRI system can monitor pancreatic islets transplanted into non-human 
primates noninvasively and repeatedly in real time 
 
 Semi-automated image segmentation algorithm can be used for the reliable identification 
of image voxels occupied by the graft and quantitative analysis of their relative 
abundance over time 
 
 The Feridex-labeled pancreatic islets maintain their insulin secretion function and, 
following autologous transplantation, do not have adverse effects on the primate’s health 
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7. General Discussion 
 
Pancreatic islet transplantation is a promising beta-cell replacement therapy for patients with 
T1DM. High rates of insulin independence can be achieved shortly after transplantation; 
nevertheless, a majority of patients resume insulin treatment in the first 5 years after receiving 
the graft. Islet transplantation is still an experimental procedure and numerous studies are being 
directed toward optimization and modification of the current methods of islet transplantation 
with the ultimate goal of long-term survival of islets. Contemporary research is concentrated on 
the development of advanced imaging modalities to evaluate morphology of transplanted islets 
and monitor their mass, distribution, and function. Noninvasive imaging is essential to a more 
detailed understanding of the dynamics of transplantation and the complex biological aspects that 
determine islet graft survival [26]. 
MRI is emerging as a technology with a high potential for islet monitoring in the clinical 
setting due to its capacity for noninvasive longitudinal assessments. Furthermore, MRI has two 
specific advantages over PET and optical imaging: higher spatial resolution (micrometers rather 
than several millimeters) and the fact that physiological, molecular, and anatomical information 
can be obtained simultaneously. Spatial resolution is a measure of the accuracy or detail of 
graphic display in the images expressed in millimeters. It is the minimum distance between two 
independently measured objects that can be distinguished separately, or in other words, how fine 
the image is [162]. High field strength MRI scanners (4.7 T, 9.4 T, 15 T) with near-microscopic 
resolutions are now available for small animal research, and 7 T magnets are already in use in 
some clinical systems. In addition, MRI is a modality which does not utilize ionizing radiation, 
has tomographic capabilities, and unlimited depth penetration through tissues [163]. 
MRI is based on the principal that unpaired nuclear spins, called magnetic dipoles (such as 
hydrogen atoms in water and organic compounds), align themselves when placed into a magnetic 
field. A strong magnet in the MRI scanner produces a magnetic field around the subject under 
examination. There are also “coils” within the magnet to produce a gradient in this magnetic 
field in the X, Y, and Z axes. In addition, the magnet contains a radiofrequency coil that can 
produce a temporary radiofrequency pulse to change the alignment of the spins. Following the 
pulse, the magnetic dipoles return to their baseline orientation, which is detected (also by the 
radiofrequency coil) as a change in electromagnetic flux (radiofrequency waves in the range 1-
100 MHz). An important function of the scanner is to determine the rate at which these dipoles 
relax to their baseline orientation. This measurement is translated into an MR signal. Dipoles in 
different physicochemical environments will have different relaxation times and thus, generate 
different MR signals. For example, dipoles in a lipid- or hydrocarbon-rich environment will have 
significantly shorter (up to 20×) relaxation times than dipoles in an aqueous environment. This is 
one of the main ways by which image contrast is achieved in MRI. The timing parameters of 
pulse excitation and recording can be altered by a central computer resulting in images with 
different types of magnetic contrast. The two most frequently used timing parameters are known 
as T1 and T2 weighting [162]. 
MRI is sensitive to soft-tissue differences and irregularities, but pancreatic islets do not stand 
out from the surrounding tissues on MR images. Incorporation of MR contrast agents into islet 
cells renders them distinct from the surrounding tissue and therefore allows the in vivo 
identification and tracking of labeled islets by MRI [154]. Superparamagnetic iron oxide (SPIO) 
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nanoparticles are widely used as a platform for many MRI contrast agents. Their basic structure 
includes an iron oxide core covered with a dextran coat that can be functionalized with additional 
imaging, targeting, or therapeutic moieties [156]. The presence of iron oxides in tissue is 
evidenced by a loss in signal intensity on T2-weighted and T2*-weighted MR images or, in 
technical terms, by a shortening of the T2 relaxation time of surrounding water protons [164], 
[130]. 
In our first studies, we developed a method for the noninvasive detection and monitoring of 
pancreatic islet grafts by dual-modality fluorescence/MRI utilizing a MR 4.7 T scanner (Paper I 
and Paper II). We used 30-nm SPIO magnetic nanoparticles (MNs) modified with the near-
infrared fluorescent Cy5.5 dye (MN-NIRF). As a result, in addition to their magnetic properties, 
these nanoparticles carried fluorochromes for optical imaging. After incubation with MN-NIRF, 
isolated islets were associated with a bright fluorescence signal in the near-infrared channel and 
appeared to be labeled with the probe. Intracellular internalization of the probe by endosomes 
was confirmed by electron and fluorescence microscopy. Labeling of human islets with MN-
NIRF did not adversely affect islet viability or islet function. MN-NIRF-labeled human islets 
transplanted under the mouse kidney capsule or into the mouse liver appeared as dark 
hypointense areas representing islet clusters and/or single islets on T2*-weighted images. There 
was a direct linear correlation between T2* values and number of labeled islets. MRI in vivo 
monitored labeled islets transplanted under the kidney capsule noninvasively and repeatedly in 
real time for up to 188 days, demonstrating graft stability and persistence of the label. We 
demonstrated that human pancreatic islets could be labeled with a magnetic imaging probe that 
could produce a sufficient signal-intensity change on magnetic resonance images without 
altering islet insulin-producing function. Jirak et al. correspondingly demonstrated the feasibility 
of labeling, detecting, and longitudinal monitoring of intrahepatically transplanted rat islets by a 
MR 4.7 T scanner. Their research group utilized a commercially available, 62 nm 
carboxydextran coated SPIO MNs based contrast agent Resovist (ferucarbotran). Hypointense 
regions in the liver were detectable on T2*-weighted images for up to 22 weeks; however, they 
gradually and slowly diminished over time. The hypointense areas did not noticeably change 
shape. They stayed homogeneously distributed throughout the whole liver and remained in the 
same position during the entire measurement period. Resovist-labeled islets preserved their 
vitality and function both in vivo and in vitro [165]. 
The definitive goal of our imaging research was its future clinical application for the 
management of patients with T1DM. For that reason, we employed a clinically relevant 
intrahepatic transplantation model in our subsequent studies (Paper III). For islet labeling we 
utilized the FDA-approved and commercially available contrast agent Feridex, which is routinely 
used in the clinic for liver neoplasm imaging. Similar to MN-NIRF, Feridex consists of SPIO 
covered with a dextran coat. When used for hepatic MRI, intravenously injected Feridex is 
rapidly cleared from the bloodstream by the hepatic reticuloendothelial system (Kupffer cells). 
The phagocytosed iron-oxide core of Feridex is broken down into other forms of iron and then 
incorporated normally into hemoglobin in newly formed erythrocytes [166]. In our study, 
labeling with Feridex did not affect islet viability or function. On MRI scans, labeled, 
transplanted islets appeared as distinct hypointense foci that were dispersed throughout the liver 
parenchyma. The relative islet mass was quantified and tracked over time by manually scoring 
the number of hypointense voxels representing islet graft on sequential MR Images.  
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We used this approach to evaluate the relative contribution of immune rejection to islet loss in 
the early posttransplantation period by comparing the change in the transplanted islet mass over 
time in immunocompetent and immunocompromised mice. The analysis showed that the number 
of islets in both models started to decline immediately after transplantation. This immediate 
decrease was consistent with islet death after transplantation due to mechanical injury, ischemia, 
and antigen-independent inflammatory events. The rate of islet loss gradually decreased during 
the course of the study and plateaued between days 10 and 14. However, immunocompetent 
mice exhibited a significantly higher rate of islet disappearance on MR images, in contrast to 
immunocompromised animals. This was especially pronounced on day 10 and resulted in a 20% 
difference in relative islet number by 14 days after transplantation, apparently due severe 
immune rejection. The MR imaging data correlated with the apoptotic rate showed by a TUNEL 
assay performed on excised livers. This rejection was evident from our correlative 
immunohistochemical studies, which confirmed that the higher rate of islet death detected by 
MRI and TUNEL assay in immunocompetent mice was due to significant immune cell 
infiltration. As a result of this study, we demonstrated that MRI could track relative mass values 
of intrahepatically transplanted islets over the time. MRI could also monitor islet death due to 
immune rejection noninvasively and repeatedly in real time. We anticipate that these studies 
could make a significant impact on allotransplantation and the development of new and 
improved immunosuppressive regiments. Immune-rejection-related islet loss was also studied in 
rats following islet labeling with Resovist and allogeneic or syngeneic transplantation of islets 
into the liver [167]. By the end of the study, 6 weeks after transplantation, rejection of the grafted 
allogeneic islets had resulted in a loss of 65% of the initially transplanted islet mass. In a recent 
study Lee et al. proved that pancreatic islet grafts and their rejection could be imaged on a 1.5 T 
clinical MRI scanner [168]. Islets were labeled by a novel magnetosome-like polyethylene 
glycol-phospholipid (PEG-phospholipid)-encapsulated magnetite nanocubes (FIONs). FIONs 
exhibited a very high relaxivity (considerably higher than Feridex) producing a strong contrast 
effect on a 1.5 T scanner, while the chemical composition of FIONs had similarities with 
Feridex. Immune rejection was studied in syngeneic and allogeneic rat models. The syngeneic 
islets transplanted into the liver were observed up to 150 days after transplantation, although the 
number and size of their hypointense spots in the T2* images progressively decreased. The 
number of dark spots representing allografted islets decreased significantly, even one day after 
transplantation. Furthermore, immunohistochemical sections of liver three days after 
transplantation showed that the infiltration of immune cells had already begun. The pattern of 
islet disappearance in allogenic rats resembled the data obtained in our study (Paper III). In 
addition, Lee et al. successfully used FIONs in a swine model of islet rejection. After the 
infusion, islets were observed in the T2* MR images as hypointense spots throughout the liver of 
animal receiving immunosuppressive therapy. On the contrary, no dark spot was shown in swine 
that did not receive immunosuppressive treatment [168].  
We found that iron distribution within islets was not uniform ranging from 11% to 67% (Paper 
III). Similar findings were described by Jiao et al., who labeled rat islet with ferucarbotran [169]. 
Our previously reported observations (Paper I) and the additional immunohistochemical and 
Prussian Blue staining (Paper III) revealed that labeling with iron oxides involves all islet cell 
types. Apparently, the labeling mostly involves the beta-cells because these cells represent the 
largest cell population in the islet. Feridex did not have any specificity toward islet cells, and 
cellular uptake was most likely associated with conventional fluid phase endocytosis. Iron 
accumulation by islets incubated with increasing concentrations of Feridex varied from 1.21 ± 
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0.36 to 18.26 ± 1.36 pg iron/islet cell for Feridex (assuming 2,000 cells/islet). These levels of 
iron uptake correlated with data published by Berkova et al. [170].  
Since there was a discrepancy about the fate of iron nanoparticles inside the islet cells after 
labeling with MNs, Berkova et al. investigated in detail the time behavior of the labeling process 
and iron accumulation in different islet cell types. Ferucarbotran particles were visualized with 
electron microscopy as characteristic irregular crystals with an extremely high electrodense core 
and a less-dense coating. After a 1-hr labeling period, ferucarbotran was found adhered on the 
endocrine cell surface, whereas few particles were already found in the endocytic structures of 
macrophages. After a 4-hr culture period, the particles were localized also in the beta-cell 
vesicles. With the prolonged labeling time, the amount of incorporated particles further increased 
and formed huge electrodense clusters. Importantly, the ultrastructure of the labeled islet cells 
was not affected; typical cytoplasmatic organelles and cell-to-cell contacts were observed. It had 
been demonstrated previously that the release of free iron from SPIO particles was dependent on 
buffering systems and pH [171]. Berkova et al. observed some endosomes that fused with 
lysosomes and were degraded, but the majority of particles remained unchanged in endosomes. 
We believe that the latter study is very important for understanding of the possible effects of 
SPIO nanoparticles on diverse aspects of cell activities. A potential toxic effect of SPIO on 
pancreatic islets has not been reported to date, and the majority of islet labeling studies 
emphasized the safety of SPIO based contrasts agents (Paper I, Paper III, Paper V), [165, 168, 
169, 172‐181]. Nevertheless, exposure of other cell lines to SPIO has been associated with some 
toxic effects such as: inflammation, the formation of apoptotic bodies, impaired mitochondrial 
function, membrane leakage of lactate dehydrogenase, generation of reactive oxygen species 
(ROS), increase in micronuclei, and chromosome condensation [182]. Therefore, more studies 
are needed to investigate the effects of SPIO-based contrast agents on islet cell ultrastructure and 
behavior.  
In our next set of experiments (Paper III), we attempted to trace the fate of the iron label after 
transplantation as a function of islet death. Immediately after transplantation in the liver, islets 
retained Feridex labeling and therefore, were visible on MR images. However, as immune 
rejection and other factors were affecting their viability, transplanted islet cells died releasing 
Feridex and decreasing its content significantly. Pancreatic islet from immunocompetent mice 10 
days after transplantation were infiltrated with immune cells, but were still maintaining some of 
the label, allowing for its detection by MRI. Interestingly, the remaining label in the islet was not 
internalized by invading cells, but stayed associated with islet cells. At the same time, as islets 
were dying, they released their content into the liver parenchyma where it was internalized and 
processed by Kupffer cells. By 14 days after transplantation, however, there was no evidence of 
iron associated with Kupffer cells or liver parenchyma, suggesting rapid clearance of the label 
consistent with the known pharmacokinetics of the compound [166]. From an imaging 
perspective, iron released by dying islet cells in small amounts diffuses throughout the liver and 
sparsely distributes over a larger area and therefore, is not expected to create “false positives” on 
MR images. In contrast, Feridex concentrated upon internalization within viable pancreatic islet 
cells creates a signal void due to compartmentalization of the label in a membrane-enclosed 
environment [183, 184]. The persistence of iron within Kuppfer cells is short-lived due to its 
rapid processing by these cells and its release into the physiologic iron pool [185]. On in vivo 
images upon release from dead or dying islets, the label loses its compartmentalization as it 
diffuses through the tissue. Using the specified gradient-echo MRI sequences, the non-
compartmentalized label (diffused into interstitium) or the label localized within a single cell 
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(e.g. internalized by a Kupffer cell) would not generate a sufficient T2* effect in order to persist 
as a signal void. Only the label compartmentalized at a high concentration within a multicellular 
structure (i.e. pancreatic islet which consists of about 2000 cells with an average diameter of 
200-400 m) would be detectable using the specified degree of T2* weighting and spatial 
resolution. A single cell of a 40-fold smaller average diameter is beyond the limit of detection of 
MRI sequences with the particular level of T2*-weighting and spatial resolution that we are 
using. Therefore, the only entity within the liver, which would retain iron at a high concentration 
and with a steady time-course, would be viable islet grafts. Lee et al in their study on rats 
described the similar fate of the iron label [168]. 
In the next study, we used MRI to investigate the relationship between hyperglycemia and islet 
graft mass (Paper IV). Feridex-labeled islets were transplanted to healthy and diabetic 
immunodeficient mice. There was a visual difference in the number of islets between the groups 
on day 5 after transplantation presumably due to the toxic effect of hyperglycemia in diabetic 
animals. Furthermore, comparison of MRI data with histochemical analysis of islet grafts 
revealed that the disappearance of pancreatic islets on MR images was due to islet death. The 
half-life of the islets in diabetic mice was on average 2.6 times shorter than in healthy animals. In 
this study, we demonstrated that the adverse effects of hyperglycemia on transplanted pancreatic 
islet graft mass can be reliably monitored over an extended period of time by noninvasive MR 
imaging. 
The next step was to evaluate the impact of islet purity on contrast agent labeling and detection 
of pancreatic islets by MR imaging (Paper IV). We found that iron uptake was significantly 
higher in high-purity islets than in low-purity islets. However, on MR images, the number of 
dark spots representing labeled islets appeared to be the same in both groups. The two groups of 
animals did not exhibit any statistically significant difference in islet disappearance rate 
throughout the study. In contrast, there was an increased islet cell death and macrophage 
infiltration in grafts contaminated with acinar and ductal tissue. These findings led us to the 
conclusion that there was a significant loss of contaminating tissue in mice transplanted with 
50% purity islets early after the procedure. Despite the fact that this contaminating tissue 
appeared lightly labeled with Feridex, its fast disappearance resulted in equal islet loss rate in 
both models. According to our immunohistochemical assessment and morphological results 
obtained by other investigators, non-islet tissue mostly disappeared during the first 2 weeks after 
transplantation, whereas islet tissue remained well preserved [186, 187]. This study demonstrated 
that transplantation of islets contaminated with nonendocrine tissue did not have any significant 
influence on MR images, presumably because of a low labeling rate of this tissue and a fast rate 
of its disappearance after transplantation. 
The subsequent experiment represented an essential intermediate step before translating MRI 
of islet transplantation from experimental to clinical applications (Paper V). We developed a 
comprehensive new method for visualization of transplanted islets (small structures 150 –200 
µm in diameter) in a large animal model. In a preclinical non-human primate (baboon: Papio 
hamadryas) model of autologous islet transplantation, we showed that islets labeled with Feridex 
could be detected in vivo by MRI. Furthermore, we described the development of a 
semiautomated image analysis algorithm for the quantitative evaluation of changes in the 
transplanted islet mass over time. Finally, we demonstrated that the labeling technique was safe 
to the animal and did not adversely affect the long-term function or survival of the animal and 
the transplanted islets.  
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In diabetic patients, pancreatic islet transplantation represents an attractive alternative to whole 
organ transplantation. However, one of the major hurdles on the way to clinical implementation 
of this procedure is an inability to monitor islet noninvasively. As outlined in this thesis, 
significant progress has been achieved towards this goal. Validation studies in mice and in non-
human primates demonstrated safety and reliability of magnetic resonance imaging for detection 
and monitoring of transplanted islets. In the future we envision application of this technique not 
only for the purpose of islet monitoring but also for image-guided therapy. To that end, the first 
steps have been taken to combine labeling of pancreatic islets with iron oxide nanoparticles and 
delivery of therapeutic load. Specifically, we attempted to deliver gene therapy to pancreatic 
islets prior to transplantation with the ultimate goal to silence genes responsible for islet damage. 
In our preliminary experiments we showed silencing of a model gene (GFP) in GFP-expressing 
islets following incubation with nanoparticles conjugated to siRNA to GFP [188]. We showed 
that siRNA conjugated to nanoparticles accumulated in isolated islets in quantities sufficient for 
detection by MRI in vitro and for silencing target model gene GFP. These investigations paved 
the way toward therapeutic studies where pancreatic islets were labeled with nanoparticles 
conjugated to siRNA targeting mRNA for caspase-3. Transplanted islets demonstrated prolonged 
survival compared to controls as shown by in vivo MRI during the initial 2-week period when 
islet destruction is the most prominent [189]. There are plans in the future to target other genes 
responsible for various aspects of islet destruction before and after islet transplantation. In 
addition, since iron oxide nanoparticles represent a convenient platform for conjugation 
chemistry, delivery of other drugs, both established and experimental, is considered as well. The 
ability to monitor islet survival following therapy is a significant benefit that these agents offer. 
This imaging modality can greatly assist clinical management of patients following pancreatic 
islet transplantation.  
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8. Final Conclusions 
 
Magnetic resonance imaging can be used for noninvasive monitoring of pancreatic islet 
transplantation: 
 human pancreatic islets can be labeled with the SPIO-MN-based contract agent ferumoxide 
(Feridex) that produces a sufficient signal-intensity change on MR images 
 ferumoxide does not alter islet vitality and insulin-producing function 
 ferumoxide-labeled islets can be monitored in vivo by MRI noninvasively and repeatedly in 
real time 
 the relative transplanted islet mass can be quantified and tracked over time by MRI 
 MRI can monitor islet death due to immune rejection or glucose toxicity noninvasively and 
repeatedly in real time 
 islet purity does not have any impact on labeling by ferumoxide 
 MRI of ferumoxide-labeled pancreatic islets can be successfully applied to a pre-clinical, non-
human primate model 
 
We anticipate that the findings obtained in these studies would ultimately result in the ability to 
detect and monitor pancreatic islet engraftment in humans, which would greatly aid in the 
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